首页> 外国专利> HYDROXYACYL-CoA DEHYDROGENASE BETA SUBUNIT MUTANT GENE WHICH CAUSES AN EARLY-ONSET AUTOSOMAL RECESSIVE AXONAL CHARCOT-MARIE-TOOTH DISEASE, AND A METHOD AND A COMPOSITION FOR DIAGNOSING THE DISEASE USING THE SAME

HYDROXYACYL-CoA DEHYDROGENASE BETA SUBUNIT MUTANT GENE WHICH CAUSES AN EARLY-ONSET AUTOSOMAL RECESSIVE AXONAL CHARCOT-MARIE-TOOTH DISEASE, AND A METHOD AND A COMPOSITION FOR DIAGNOSING THE DISEASE USING THE SAME

机译:羟酰基-CoA脱氢酶β亚基突变基因,其引起早发型自发性慢性轴索性炭疽病,以及使用该方法诊断疾病的方法和组合物

摘要

PURPOSE: A diagnosis using a hydroxyacyl-CoA dehydrogenase beta subunit (HADHB) mutant gene is provided to accurately and early diagnose an autosomal recessive axonal Charcot-Marie-Tooth disease (CMT) through a gene or protein test, to maximize treatment effect, and to enable personalized therapy according to the cause of the disease.;CONSTITUTION: An HADHB mutant gene is a marker for diagnosing an autosomal recessive axonal CMT. In the HADHB mutant gene, exon 5 of HADHB gene is deleted by substitution of 686th base, guanine to thymine, in a base sequence of sequence number 1, and substitution of the last base of an intron 4 base sequence between 209th and 210th bases, guanine to cytosine, in a base sequence of sequence number 2. A composition for diagnosing an early-onset autosomal recessive axonal CMT contains an agent which is able to detect the expression of mRNA of the HADHB mutant gene or the expression of Hadhb mutant protein encoded by the gene. A method for providing necessary information for diagnosing the possibility of developing an early-onset autosomal recessive axonal CMT comprises the steps of: detecting the expression of the mRNA or the protein from an individual sample; and determining high possibility of developing the early-onset autosomal recessive axonal CMT when the mRNA or the protein is expressed in an individual sample.;COPYRIGHT KIPO 2013;[Reference numerals] (AA) Healthy person; (BB) Patient
机译:目的:提供一种使用羟酰基辅酶A脱氢酶β亚基(HADHB)突变基因的诊断,以通过基因或蛋白质测试准确,早期地诊断常染色体隐性轴索性夏洛特-玛丽齿病(CMT),以最大程度地提高治疗效果,以及以便根据疾病的原因进行个性化治疗。;组成:HADHB突变基因是诊断常染色体隐性轴突CMT的标志物。在HADHB突变基因中,通过在序列号1的碱基序列中将686鸟嘌呤取代为胸腺嘧啶,并在209到210之间的内含子4碱基序列的最后一个碱基取代,来删除HADHB基因的外显子5,鸟嘌呤到胞嘧啶,序列号为2。位于诊断早发型常染色体隐性轴突CMT的组合物中,该试剂含有能够检测HADHB突变基因的mRNA表达或编码的Hadhb突变蛋白的表达的试剂。通过基因。一种提供必要信息以诊断发生早发性常染色体隐性轴突CMT的方法,该方法包括以下步骤:检测单个样品中mRNA或蛋白质的表达; COPYRIGHT KIPO 2013; [参考数字](AA)健康人;在个体样品中表达mRNA或蛋白质时,确定发生早发型常染色体隐性轴突CMT的可能性很高。 (BB)病人

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号